Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PHGDH | O43175 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23113264 | 0.92 | HPGD (0.58) | HPGDALDH1A1LMNANPSR1HTT | |
| SCHEMBL12846471 | 0.89 | HPGD (0.54) | HPGDALDH1A1LMNAHTTKDM4E | |
| SCHEMBL12547814 | 0.89 | HPGD (0.54) | HPGDALDH1A1LMNANPSR1HTT | |
| SCHEMBL12546097 | 0.86 | HSP90AA1 (0.53) | HPGDALDH1A1LMNAHTTKDM4E | |
| SCHEMBL15108842 | 0.86 | HPGD (0.51) | HPGDALDH1A1LMNANPSR1HTT | |
| SCHEMBL15219384 | 0.85 | HIF1A (0.52) | HPGDALDH1A1LMNAHTTKDM4E | |
| SCHEMBL19657227 | 0.85 | HPGD (0.50) | HPGDALDH1A1LMNAHTTKDM4E | |
| SCHEMBL20888504 | 0.83 | HPGD (0.49) | HPGDALDH1A1LMNAHTTKDM4E | |
| SCHEMBL23113214 | 0.83 | KDM4E (0.65) | HPGDALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL7491 | 0.83 | HPGD (0.71) | HPGDALDH1A1LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9272248-B2 | Gas separation composite membrane, and gas separating module, gas separation apparatus and gas separation method using the same | FUJIFILM CORPORATION (JP) | 2016-03-01 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20140130669-A1 | GAS SEPARATION COMPOSITE MEMBRANE, AND GAS SEPARATING MODULE, GAS SEPARATION APPARATUS AND GAS SEPARATION METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2014-05-15 | — | — | US | disclosed |
| EP-2473491-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2011025565-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-03 | — | — | WO | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-6943194-B1 | Synthesis of phenstatin and prodrugs thereof | ARIZONA BOARD OF REGENTS, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2005-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | HPGD 3092/4885ALDH1A1 2444/4885LMNA 95/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | HPGD 3950/4885ALDH1A1 2289/4885LMNA 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.